Lilly to develop encapsulated diabetes cell therapies through Sigilon deal – In-PharmaTechnologist.com
In-PharmaTechnologist.com |
Lilly to develop encapsulated diabetes cell therapies through Sigilon deal
In-PharmaTechnologist.com Eli Lilly has licensed Sigilon Therapeutics' technology to develop encapsulated cell therapies for the treatment of type 1 diabetes. Under the terms, Sigilon will use its Afibromer platform to 'encapsulate' – the process of immobilising cells with a … Lilly researches cell therapies for type 1 diabetes with Sigilon Lilly and Sigilon partner to develop diabetes type I therapies |
